Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation of Initial Treatment Pattern and Overall Survival in the Chinese Muscle Invasive Urothelial Bladder Carcinoma Patients.

NCT03433924 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03433924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03433924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation of Initial Treatment Pattern and Overall Survival in the Chinese Muscle Invasive Urothelial Bladder Carcinoma Patients.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 18, 2020
Completion date
March 27, 2023
Enrollment
248 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder cancer